Noveris Health Sciences is trading 6.7% down at CA$0.07, with no clear company-specific catalyst identified for October 6, 2026.
- The latest company news surfaced was its September 9 annual and special meeting announcement; the CSE news page showed no newer release in the retrieved listing.
- Biotechnology shares were under pressure, with XBI down 2.50%, which may provide background but does not establish the cause. Broader U.S. indexes were higher, so broad-market weakness is not a clear explanation.